Marc Beer Impact Towards Renovia

Marc Beer, an expert in development and commercialisation of biotechnology, pharmaceutical, devices and diagnostics, has contributed $42 M to support women`s health. He founded Renovia Inc. together with Ramon Iglesias, Yolanda Lorie and MD in 2016 and successfully closed a series A financing with the leading healthcare investment capital funds. Marc Beer is also the Chairman and Chief Executive Officer of this Boston based Medtech Company.

 

Renovia Inc. has been operational since its establishment producing products for treating pelvic floor disorders which include urinary incontinence. According to researches carried out, it is estimated that about 250 million women globally suffer from pelvic floor disorders. Leva, which is the first product from Renovia received FDA approval on April 2018.

 

The money raised was to be used in financing programs to develop four more therapeutic and diagnostic products as well as improvising new products of Leva devices. The financing was led by New York-based Perceptive Advisors, Ascension Ventures from Missouri and the Longwood Fund, a healthcare-focused investment firm which had also previously invested in series A.

 

Marc Beer on behalf of Renovia Inc. management team appreciated the support they had been receiving from these healthcare investors who had a similar goal of helping and improving lives of women suffering from pelvic floor disorders in the world. He added that through combining innovative skills and proprietary technologies will help the company develop a new digital platform. The digital platform aims at providing valuable information to all patients on the new diagnostic and treatments offered by Marc Beers Company at relatively low costs.

 

Marc Beer has received many awards for being a good leader and for his efforts to improve the health industry. Renovia Company is made up of a group of experts who foresee its development and growth. Some of the leader who work alongside Marc Beer include; William Dull who is the Chief Commercial officer, Dr. Samantha Pulliam, MD the Chief Medical Officer, Jose Bohorquez, PhD the Chief Scientific Officer and Jessica McKinney, PT, MS, CMPT who serves as the Vice president of all medical affairs and even Clinical Advocacy.

 

Before joining Renovia, Marc Beer was the founder of ViaCell Company that specializes with collection and preservation of blood stem cells for the umbilical cord. He has also served in various organizations related to health industry including NASDAQ a publicly traded biopharmaceutical Company. While working at Genzyme Marc Beer promoted the establishment of multiple products that addressed numerous diseases. Working at these companies earned Marc Beer different experiences. Marc Beer is a member of the Notre Dame Graduate Studies Research and the advisory council. Learn more: https://renoviainc.com/leadership/

Marc Beer’s Renovia Raises $42 Million After Series B Round

Marc Beer has an experience of 25 years as a seasoned executive when it comes to the commercialization and development in the pharmaceutical, diagnostic, and biotechnology industries. He earned a B.S. from Miami University. For 7 years, since the company’s inception, he held the role of founding Chief Executive Officer at ViaCell, which is a biotechnology company that specializes in both collecting and preserving blood stem cells from umbilical cords.

 

 

In addition, he had various titles within Genzyme, which is a specialty care company that aimed to develop treatments for diseases which are difficult to both diagnose and treat. He was also the strategic consultant of OvaScience, a biotech company which is publicly traded company, and that announced a merger with Milendo Therapeutics (Michigan-based). His long resume also includes his work with Abbott Laboratories, where he helped with the promotion of the pharmaceutical and diagnostic divisions. He founded Good Start Genetics, Inc., a molecular diagnostics company, where he acted as the chair of the company’s compensation committee. The company got purchased by Invitae, and now focuses on genetic tests for pediatric and adult inherited conditions.

 

 

In 2016, Marc Beer alongside Yolanda Lorié, and Ramon Iglesias founded Renovia in Boston, Massachusetts. The startup aims to develop a number of products designed for pelvic floor disorders, closing their Series B round at $32 million, with $10 million in venture debt. The Boston-based company is addressing issues like urinary incontinence by trying to develop various therapeutic and diagnostic products. Research shows that approximately 250 million women around the globe are affected by urinary incontinence. Leva, the first product developed by Renovia, has already been approved by the FDA in April.

 

 

The Longwood Fund is an early investor in the Renovia startup, being an investing firm which is focused on the healthcare industry. The Longwood Fund have joined the Series B round, the round being led by Perceptive Advisor (a company based in New York) , and Ascension Ventures (a company based in Missouri). The new round of funding will go towards both the development and the testing procedures of 4 new therapeutic and diagnostic products, which includes a new generation of Leva.

 

 

Marc Beer declared in a statement that Renovia is thrilled to have the support of healthcare investors who are sharing the same vision as the company to improve the lives of women affected by the disorders with better diagnosis and treatment. He also noted that the combination of their form factors and sensor technologies with a digital health platform will offer the customers important data in order to inform about new treatment options, and drive greater understanding about pelvic floor disorder, with the ultimate goal being lowering healthcare costs in the long term. Learn more : https://renoviainc.com/leadership/